Beam Therapeutics

Beam Therapeutics, Inc. develops and commercializes DNA base editing technologies for the treatment of human disease. Its licensed technology platform, which includes access to base editing technologies and associated technologies that enhance the scope of base editing. The company was founded by David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli, and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Beam Therapeutics excels in base editing therapies, poised for growth

Beam Therapeutics showcased strong performance in trials and technology development, positioning itself as a leader in base editing therapies.
While facing challenges in clinical translation and regulatory landscapes, Beam's focus on innovative solutions presents growth opportunities in gene editing.
Overall, Beam's financial strength, promising data, and strategic vision offer a solid foundation for future success in the biotech industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. Its pipeline includes BEAM-101, BEAM-302, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-301, and BEAM-201. The company was founded by David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli, and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.

Fate Therapeutics

10X Genomics

3 Hot Healthcare Stocks Cathie Wood Is Buying in April

Cellectis SA

CRISPR Therapeutics

Editas Medicine

Intellia Therapeutics

The biotech space is on the verge of hypergrowth, thanks to a scientific breakthrough in genetic editing. This is your ultimate guide to understanding and profiting from CRISPR stocks.

Investing in CRISPR Stocks: Ultimate Genetic Editing Guide

Company On-track to Submit First IND with BEAM-101 in the Second Half of 2021

Beam Therapeutics Announces Business and Pipeline Progress and Reports Fourth Quarter and Full Year 2020 Financial Results

CAMBRIDGE, Mass., March 15, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that drug development expert Amy Simon, M.D., has been appointed as the company's chief medical officer. Dr. Simon brings more than 20 years of clinical experience to Beam, serving in roles as a physician-scientist in academia and the biotechnology industry.

Beam Therapeutics Appoints Amy Simon, M.D., Chief Medical Officer

bluebird bio

Gene editing stocks are on the move Wednesday with investors taking extra interest in biotech companies on news from two major players. The post Gene Editing Stocks: What BLUE, NTLA, BEAM, CRSP and EDIT Are Doing Today appeared first on InvestorPlace.

Gene Editing Stocks: What BLUE, NTLA, BEAM, CRSP and EDIT Are Doing Today

CAMBRIDGE, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer, will participate in a fireside chat during the Barclays 2021 Global Healthcare Conference on Thursday, March 11, 2021 at 2:25 p.m. ET.

Beam Therapeutics to Participate in the Barclays 2021 Global Healthcare Conference

Beam Therapeutics Inc (NASDAQ: BEAM) acquires Guide Therapeutics (GuideTx), a developer of nonviral drug delivery vehicles for genetic medicines, in an all-stock deal for $120 million upfront. GuideTx shareholders could also yield up to $320 million more in milestone payments.

Beam Therapeutics Adds To Drug Delivery With $120M GuideTx Buy

Beam Therapeutics announced it had acquired Guide Therapeutics, a maker of components for genetic medicines — and Beam stock tumbled. Broadly, biotech stocks were under pressure.

Beam Therapeutics Dives On $120 Million Takeover Of Guide Therapeutics

GuideTx's Proprietary LNP Screening Technology and Lipid Library Supports Expanded Targeting of Diverse Tissues for In Vivo Delivery of Gene Editing GuideTx's Proprietary LNP Screening Technology and Lipid Library Supports Expanded Targeting of Diverse Tissues for In Vivo Delivery of Gene Editing

Beam Therapeutics Announces Acquisition of Guide Therapeutics

Beam Therapeutics is a preclinical stage gene editing company that has continued to go up and up. Two ASH publications in December may be responsible.

Beam Me Up, Scotty

Beam Therapeutics (BEAM) is pioneering a new evolution of gene editing techniques that could be the key to making safer genomic medicines. The post This Unique Gene Editing Stock Could Turn into the Genomic Revolution's Biggest Winner appeared first on InvestorPlace.

This Unique Gene Editing Stock Could Turn into the Genomic Revolution's Biggest Winner

SpringWorks Therapeutics Inc

Among the public companies that made the BioSpace list of the top up and coming life sciences firms in 2019 and 2020, the majority have seen gains in their share prices. Given this metric, investors might want to track the progress of those still-private firms in the event they take the initial public offering route down the line.

Beam, SpringWorks Biggest Gainers on BioSpace List

CAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM) (the “Company”), a biotechnology company developing precision genetic medicines through base editing, today announced that it has agreed to sell 2,795,700 shares of its common stock to certain institutional investors in a private placement. The Company anticipates aggregate gross proceeds from the offering will be approximately $260 million, before deducting fees to the placement agents and other estimated offering expenses payable by the Company, based on the offering price of $93.00 per share, representing an approximately 10% discount to the 5-day volume weighted average share price. The financing syndicate includes Perceptive Advisors, Farallon Capital, Casdin Capital, Redmile Group and Cormorant Asset Management, among others. The closing is anticipated to occur on January 21, 2021, subject to customary closing conditions. The Company intends to use the net proceeds from the offering to support clinical development, to pursue strategic partnerships and general corporate purposes.

Beam Therapeutics Inc. Announces $260 Million Common Stock Investment from Multiple Investors

Calyxt

Sangamo Therapeutics

Between these seven genetic editing pioneers, you have the widest exposure to the biggest scientific breakthrough of the century. The post 7 CRISPR Stocks for the Future of Medicine appeared first on InvestorPlace.

7 CRISPR Stocks for the Future of Medicine

CAMBRIDGE, Mass., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that Kate Walsh, president and chief executive officer of the Boston Medical Center (BMC) health system, has joined the company's board of directors. BMC is a private, not-for-profit, academic medical center with a community-based focus and is the primary teaching affiliate of Boston University School of Medicine.

Beam Therapeutics Appoints Leading Healthcare Executive Kate Walsh to its Board of Directors

Investors need to pay close attention to Beam Therapeutics (BEAM) stock based on the movements in the options market lately.

Implied Volatility Surging for Beam Therapeutics (BEAM) Stock Options

CAMBRIDGE, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer, will present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 12, 2021 at 11:40 a.m. ET.

Beam Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference

ARK Genomic Revolution Multi-Sector ETF

Beam Global

EHang Holdings Ltd - ADR

Ford Motor Company

Gigcapital2

Luminar Technologies

Li Auto Inc.

Oaktree Acquisition Corp

QuantumScape

Toyota Motor

Tesla

Volkswagen AG

XPeng

Listen in to hear how you can profit in 2021 and beyond

MoneyLine Podcast: These Stocks are Making MASSIVE Moves

If analysts are even close to being on target, it may be time for early investors to cash in on their shares of Beam Therapeutics Inc. (NASDAQ:BEAM). The stock of the Cambridge, Massachusetts-based biotechnology company closed at $67.68 Monday, up over 12% for the day and more than tripling since early February.

Beam Shares Have Tripled Since Early February

Beam Therapeutics was co-founded by David Liu, who invented base editing and prime editing technologies for gene editing. David Liu also co-founded Editas.

Beam Therapeutics: Early Stage Gene Editing Company With Cutting Edge Technology

BEAM-101 Data Highlight Precision of Base Editor with No Off-Target Editing Observed ; Will Support Planned IND Submi ssion in the Second Half of 2021

Beam Therapeutics Presents Updated Data from Novel Base Editing Programs for Sickle Cell Disease at ASH 2020

Magazine honors company for second year in a row Magazine honors company for second year in a row

The Boston Globe Names Beam Therapeutics a Top Place to Work for 2020

Novel Base Edit ors for Two Most Common GSDIa Mutations Demonstrate Significantly Higher Levels of In Vivo Mutation C orrection than Required to Restore Glucose H omeostasis

Beam Therapeutics Presents First Data Highlighting Base Editing Program for Glycogen Storage Disease Type Ia at AASLD

BEAM -201 , a n Off the Shelf Allogeneic CD7-Targeting CAR-T , Named as Development Candidate for Treatment of T-ALL ; First Cell Therapy Featuring Four Simultaneous Genetic Edits ; Demonstrates 96-99% On-target E diting and In Vivo Proof of Concept of Tumor Clearance

Beam Therapeutics Announces Business and Pipeline Progress and Reports Third Quarter 2020 Financial Results

BEAM-201, an Off the Shelf Allogeneic CD7-Targeting CAR-T, Named as Development Ca ndidate for Treatment of T- Cell Acute Lymphoblastic Leukemia

Beam Therapeutics Names First CAR-T Base Editing Development Candidate for the Treatment of T-ALL and Presents New Data at SITC 2020

News for Beam Therapeutics Stock (BEAM)